Multi-Cancer Early Detection Blood Tests: Promise and Present Limits

What's actually established: cell-free DNA blood testing

Multi-cancer early detection (MCED) tests work by sequencing cell-free DNA that circulates in blood plasma and looking for methylation patterns characteristic of tumor-derived DNA. The underlying laboratory method, cell-free DNA sequencing, is well established and already used clinically for other purposes: noninvasive prenatal testing, transplant rejection monitoring, and tracking molecular residual disease in patients already diagnosed with cancer.

That track record is why MCED tests moved quickly into large prospective studies. But using the same underlying chemistry to screen asymptomatic, previously healthy adults for an unknown cancer is a different clinical question, with a different bar for evidence, than using it to monitor a cancer a patient already has. This review covers only the asymptomatic screening use.

What the evidence for population screening actually shows

The most cited prospective evidence comes from PATHFINDER, a cohort of 6,662 asymptomatic adults aged 50 and older who took the Galleri test alongside their normal care. A cancer signal was detected in 1.4% of participants. Of those signal-positive results, only 38% were confirmed to have cancer after a full diagnostic workup, meaning 62% were false positives that led to scans, biopsies, or specialist visits for a cancer that was not there.[1]

A larger, more recent look at real-world use outside a research protocol tells a similar story. Across more than 111,000 people tested through ordinary US clinical practice, not a research cohort, a cancer signal was flagged in 0.91% of tests, and the positive predictive value among those with recorded diagnostic outcomes was under 50%. When the test did correctly flag a true cancer, it predicted the right anatomical origin in 87% of cases, which is useful for directing follow-up, but it does not change the fact that roughly half of positive results in ordinary practice were false alarms.[2]

The trap: a positive signal is not a diagnosis, and finding more cancer is not the same as fewer cancer deaths

Two things get blurred in how these tests are often marketed. First, a cancer signal detected result is a screening result, not a diagnosis; it triggers imaging, biopsy, or specialist referral, and in more than half of PATHFINDER's positive cases, and roughly half of real-world cases, that workup found nothing. Second, finding more early cancers on a test is not proof that a screening program reduces suffering or saves lives. Overdiagnosis, detecting a slow-growing cancer that would never have caused harm in a person's lifetime, is a real risk with any sensitive screening test, and none of the MCED studies published so far can rule it out, because none has followed participants long enough, or with a proper control arm, to compare cancer deaths between a screened and unscreened group.[1][2]

The central null finding: NHS-Galleri's primary endpoint was negative

NHS-Galleri is the largest randomized controlled trial of this technology, enrolling roughly 142,000 adults aged 50 to 77 in England and following them through three rounds of annual screening. Its primary endpoint, a statistically significant reduction in stage III or IV cancer diagnoses in the screened group compared with usual care, was not met (incidence rate ratio 1.03, 95% CI 0.92 to 1.14, p equals 0.63). That is a genuine negative result on the trial's own main question, and it belongs in any honest account of this technology.[3]

The trial did report an encouraging secondary and subgroup signal: within a prespecified group of 12 more aggressive cancers, stage IV diagnoses trended down with each successive annual screening round, roughly 9%, 22%, and 26% relative reductions across rounds one through three, and test specificity was high at 99.6%. These numbers are worth watching, but they come from a subgroup and secondary analysis reported after a negative primary result, and as of this review only conference presentation and press-release topline data are available; the full peer-reviewed manuscript has not yet been published. That is meaningfully weaker evidence than a positive, published primary endpoint, and it should be weighted accordingly until the complete data are available and independently reviewed.[3]

What remains uncertain

No study of an MCED test has yet reported whether screening with one reduces cancer mortality, which is the outcome that ultimately matters to a patient. PATHFINDER and the real-world cohort describe diagnostic yield and false-positive burden but have no control arm, so they cannot show whether people who tested positive and were found to have cancer actually did better than they would have without the test. NHS-Galleri is designed to eventually address the mortality question but has not done so yet, and its primary staging endpoint was negative.[1][2][3]

It also is not yet known how these tests perform in people under 50, in people with significant comorbidities, or across the range of ethnic and genetic backgrounds seen in a typical European clinic population, since the largest studies to date are US and UK cohorts of adults aged 50 and older.

What this means for you

AION does not offer multi-cancer early detection blood tests as a stand-alone screening program, and does not present a positive or negative MCED result as a diagnosis in itself. Diagnostics at AION start with a physician conversation about a patient's actual risk factors, family history, and existing age-appropriate screening such as colonoscopy, mammography, low-dose CT, or cervical screening, because those are the tools with a proven mortality benefit for their respective cancers.

If a patient specifically wants an MCED test, a physician walks through the real PATHFINDER and real-world numbers, including the substantial chance that a positive result is a false alarm, before anything is ordered, and any positive signal is followed by the same physician-directed diagnostic workup AION uses for any other abnormal finding, not a fixed protocol. As NHS-Galleri's full data and other ongoing trials mature, AION's position on this class of test will be revisited at the next scheduled review.